Can L. reuteri Help Periodontitis? The ER-Stress Evidence

Lactobacillus reuteri may modestly improve periodontal treatment outcomes when added to professional scaling and root planing (SRP). The most interesting new claim is biological: one 2025 randomized trial found lower markers of endoplasmic reticulum (ER) stress, a cellular response linked to osteoclast activity and bone loss. That finding is plausible, but one trial cannot settle a mechanism—or prove that a lozenge preserves jawbone.

The practical point comes first. For adults receiving SRP for periodontitis, L. reuteri has shown additional improvements in probing depth and clinical attachment level in many, though not all, published trials. It is an adjunct to treatment by a dental professional, not a substitute for removing plaque and calculus below the gumline.

A proposed route from cellular stress to bone loss

In a 2025 double-blind, placebo-controlled trial by Lu et al., 120 people received SRP plus either L. reuteri or placebo for eight weeks. The probiotic dose was 1×10⁹ colony-forming units per day. Compared with SRP alone, the probiotic group had approximately 36% lower GRP78 and CHOP, two markers used to track ER stress.

ER stress can promote osteoclast differentiation, the process by which cells resorb bone. Lower GRP78 and CHOP therefore provide a reasonable hypothesis for how L. reuteri might influence alveolar bone loss. They do not prove that this pathway caused any clinical benefit. Biomarkers are clues, not a surveillance camera pointed at causation.

The same trial also reported reductions in inflammatory markers: TNF-α fell from 30.01±5.15 to 16.57±3.88 pg/mL (45.3%), IL-6 from 25.84±3.11 to 14.35±2.16 pg/mL (45.2%), and CRP from 6.41±1.18 to 2.68±1.04 mg/L (57.8%). The paper reported all three changes as statistically significant at p<0.05. These are substantial biomarker shifts over eight weeks, but the publication does not establish whether they predict fewer lost teeth or durable protection from bone loss.

The trial deserves careful reading before anyone puts ER-stress suppression on a supplement label. Its cohort combined 84 people with Stage III–IV periodontitis and 36 with gingivitis. Gingivitis does not include baseline alveolar bone loss, so combining those groups complicates any claim about bone protection. The finding also lacks independent replication.

The clinical signal is real, but uneven

A 2024 systematic review by Ram et al. examined 11 randomized trials totaling 369 participants aged 18 to 70. In eight of 11 trials, adding L. reuteri to SRP produced a statistically significant between-group improvement in probing depth. Seven of 11 found a statistically significant gain in clinical attachment level.

Those proportions support cautious interest, not a universal recommendation. Three trials found no significant extra probing-depth benefit, and four found no significant difference in attachment level. The review could not identify whether strain, dose, delivery method, duration, or patient population separated the positive trials from the null trials.

Bias concerns also limit confidence in the apparent consistency. Using the ROB2 tool, the review rated four of the 11 trials at high risk of bias and the other seven as having some concerns. That does not erase the signal, but it means the average effect may look larger or more reliable than future well-designed trials will show.

Broader evidence syntheses reach a similar direction of travel. A 2024 network meta-analysis evaluated probiotics used with non-surgical periodontal treatment, while a 2026 umbrella meta-analysis combined evidence from systematic reviews of probiotic supplementation in periodontitis. Both support an adjunctive benefit for probiotics as a class. Neither resolves whether one specific L. reuteri strain works best.

Strain identity is not a footnote

"L. reuteri" is not enough information to predict an outcome. Existing reviews pool strains such as DSM 17938, ATCC PTA 5289, and dual-strain Prodentis products without strain-specific outcome analyses. The commonly studied protocol is roughly 10⁸ to 10⁹ CFU daily for eight to 12 weeks, but no trial series has established the minimum effective dose.

This matters because probiotic effects can differ sharply by strain. A 2025 systematic review of Lactobacillus strains and Porphyromonas gingivalis found inhibitory activity across multiple Lactobacillus species, while also showing why genus-level claims are too broad. A probiotic label is not a mechanism.

What about periodontal pathogens?

There is some human evidence that probiotics can shift the bacterial environment associated with periodontitis. A 2024 randomized trial by Şahin et al. reported reductions in the red-complex pathogens P. gingivalis, Tannerella forsythia, and Treponema denticola with probiotic supplementation in a periodontal population.

For L. reuteri specifically, a 2026 prospective RT-PCR study followed 52 people with peri-implantitis. The group receiving subgingival L. reuteri plus mechanical debridement had a greater reduction in P. gingivalis than the debridement-only group, alongside improved pocket depth and attachment measures. The authors reported p=0.00 for the bacterial comparison.

This is an early microbiological signal, not direct confirmation for ordinary periodontitis. Peri-implantitis occurs around titanium implants, where anatomy, biofilm behavior, and immune responses differ from those around natural teeth. The study was prospective and non-randomized. A prior systematic review of peri-implant disease also found a limited evidence base.

Systemic inflammation raises the stakes, not the certainty

Periodontitis treatment may affect more than the mouth. In people with type 2 diabetes, a 2024 meta-analysis found that non-surgical periodontal therapy improved systemic inflammatory and oxidative-stress markers. Other reviews report changes in arterial-stiffness measures and cardiovascular risk biomarkers after periodontal treatment.

These findings concern periodontal therapy broadly, not L. reuteri. They make effective treatment worth taking seriously; they do not show that a probiotic lowers cardiovascular risk or improves diabetes outcomes.

Who should be cautious?

The available trials do not answer the questions most relevant to people at highest risk. The 2025 mechanistic trial excluded people who were immunocompromised, had diabetes, or had severe cardiovascular, liver, or kidney disease. There are also no data on whether benefits remain three to six months after stopping the probiotic, and no head-to-head trials against systemic antibiotics, chlorhexidine chips, or minocycline microspheres.

For a systemically healthy adult already receiving SRP for Stage III–IV periodontitis, L. reuteri at studied doses is a reasonable topic to discuss with a periodontist. The clinical evidence suggests possible added benefit. The ER-stress result is a promising hypothesis that needs a second independent trial.

The evidence supports a measured conclusion: L. reuteri may improve short-term clinical measures when added to professional periodontal care, and it may influence inflammatory, microbial, and ER-stress markers. It has not shown durable tooth retention, proven alveolar-bone preservation through ER-stress suppression, or established safety and efficacy in medically complex patients. SRP remains the treatment doing the heavy lifting.